The optimal outcome for a patient with major depressive disorder (MDD) is a full recovery from the major depressive episode and to never become depressed again.5 Treatment of MDD is divided into three phases, corresponding to different stages of the illness.6 Each of these phases has a different treatment goal.6

Acute treatment phase
‘Acute phase treatment’ of MDD occurs during a major depressive episode; it runs from the initiation of treatment until remission is achieved.1,3 The goals of acute phase treatment are to achieve remission (removal of symptoms, such that the criteria for a major depressive episode are no longer met), and an improvement in functioning and quality of life.2,3 Remission is a clinically-meaningful endpoint: patients who achieve remission are less likely to relapse than those who do not achieve remission.7,8 Response, i.e., a 50% improvement from baseline in a depression rating scale score, is an intermediate treatment goal; it is used to evaluate whether or not a treatment is benefiting the patient.3

Continuation treatment phase
‘Continuation phase treatment’ of MDD follows on from acute phase treatment, i.e., it starts when remission is achieved.1,3 The goals of continuation phase treatment are to prevent a relapse (a return of symptoms sufficient to meet the criteria for a major depressive episode) in the vulnerable period immediately following remission, to eliminate any unresolved symptoms, and to restore the patient’s level of psychosocial and occupational functioning – at least to levels seen prior to the current episode and, if possible, to levels seen prior to the onset of MDD.2,3 Continuation phase treatment continues until recovery is achieved (the end of a major depressive episode).3 The moment of recovery is difficult to identify in clinical practice.3

Maintenance treatment phase
‘Maintenance phase treatment’ of MDD follows on from continuation phase treatment, provided the patient did not experience a relapse.1,3 The goals of maintenance phase treatment are to prevent a new episode of depression (recurrence), to prevent suicide, and to enable full and lasting functional recovery.3 Typically, maintenance treatment is indicated in patients with chronic/recurrent MDD (i.e., those susceptible to recurrence).2

References:
1.Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry 1991; 52 (Suppl 5): 28–34.

2.American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder. 3rd Edition. © American Psychiatric Association, 2010. http://psychiatryonline.org/guidelines.aspx. Accessed April 2025.

3.Bauer M, Pfennig A, Severus E, et al.; World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Unipolar Depressive Disorders. WFSBP guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry 2013; 14 (5): 334–385.

4.Lam RW, McIntosh D, Wang J, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 1. Disease Burden and Principles of Care. Can J Psychiatry 2016; 61 (9): 510–523.

5.Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry 2001; 62 (Suppl 16): 5–9.

6.Sadock BJ, Sadock VA, Ruiz P (eds). Kaplan & Sadock’s Comprehensive Textbook of Psychiatry. 9th Edition. Vol 1–2. © Lippincott Williams & Wilkins, 2009.

7.Nelson JC, Pikalov A, Berman RM. Augmentation treatment in major depressive disorder: focus on aripiprazole. Neuropsychiatr Dis Treat 2008; 4 (5): 937–948.

8.Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163 (11): 1905–1917.